1 Therapies|Clear filters
Reg. name: Kyprolis®
Class: Proteasome Inhibitor
Carfilzomib is an epoxomicin derivate which irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. The proteasome is responsible for degrading a large variety of cellular proteins. Inhibition of this process results in an accumulation of polyubiquitinated proteins, leading to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.
KYPROLIS® in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
|Disease:||Relapsed/refractory patients, General MM,|